This is an unusual time, and this year’s LEAP reflects it well: we start with Covid-19’s very sickest patients, and a Hopkins-wide team’s groundbreaking efforts to illuminate an unusual response in their immune system.
We end with a remarkable patient with a rare autoimmune disease: the legendary musician, Peter Frampton, who is not only raising awareness and research funding, but changing medical advice about how to preserve muscle function.
Any builder will tell you that strength lies in the crosspieces, where framework or walls intersect.
This issue of LEAP celebrates intersections: between clinicians and biological scientists, between both of those groups and information scientists, between specialists of different disciplines.
Alice in Wonderland may come to mind as you read this issue of LEAP, because we are moving from the large to the small, and back again: A rheumatic disease is big, and its effect can be devastating. However, a disease such as rheumatoid arthritis, scleroderma, or Sjögren’s is, in fact, multiple diseases, each slightly different.
Summary The study shows that deep machine learning can be utilized to more accurately identify erythema migrans rashes in early Lyme disease. Recognition of the EM rash is crucial to […]
This study uses a neuroimaging radiotracer with positron emission tomography (PET) to quantify cerebral glial activation in brains of patients with post-treatment Lyme disease. Results show elevated central nervous system immune activation in patients with PTLDS as compared to controls.
Our results indicate that substantial differences exist in how myositis is perceived by patients compared to healthcare providers, with different items prioritized.
